Time to pain relief: A randomized controlled trial in the emergency department during vaso‐occlusive episodes in sickle cell disease. (23rd January 2023)

• Record Type: Journal Article
• Authors: Tanabe, Paula; Bosworth, Hayden B.; Crawford, Regina D.; Glassberg, Jeffrey; Miller, Christopher N.; Paice, Judith A.; Silva, Susan
• Is Part Of: European journal of haematology. Volume 110:Number 5(2023)
• Page Start: 518
• Page End: 526
• Publication Date: 2023-01-23
• Subjects: emergency -- pain -- sickle cell -- vaso‐occlusive episodes; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13924
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Objective: Compare time to pain relief (minimum of a 13 mm and 30% reduction) during an Emergency Department (ED) visit among patients with sickle cell disease (SCD) experiencing severe pain associated with a vaso‐occlusive episode who were randomized to receive either an individualized or weight‐based pain protocol. Methods: A randomized controlled trial in two EDs. Adults with sickle cell disease. Research staff recorded pain scores every 30 min during an ED visit (up to 6 h in the ED) using a 0–100 mm visual analogue scale. Analysis included 122 visits, representing 49 patients (individualized: 61 visits, 25 patients; standard: 61 visits, 24 patients). Results: Pain reduction across 6‐h was greater for the individualized compared to the standard protocol (protocol‐by‐time: p = .02; 6‐h adjusted pain score comparison: Individualized: M = 29.2, SD = 38.8, standard: M = 45.3, SD = 35.6; p = .03, Cohen d = 0.43). Hazards models indicated a greater probability of 13 mm (HR = 1.54, 95% CI = 1.05, 2.27, p = .03) and 30% (HR = 1.71, 95% CI = 1.11, 2.63, p = .01) reduction in the individualized relative to the standard protocol. Conclusions: Patients who received treatment with an individualized protocol experienced a more rapid reduction in pain, including a 13 mm and 30% reduction in pain scores when compared to those that received weight‐based dosing.